Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00378573 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Incidence of GI Perforation

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: docetaxel
DRUG: gemcitabine
DRUG: bevacizumab

Sponsor

Sanofi